Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Teva Halts Tests of Cancer Drug Biosimilar

FDAnews Drug Daily Bulletin

Oct. 5, 2012 | Vol. 9 No. 196

Teva Halts Tests of Cancer Drug Biosimilar

Teva Pharmaceutical has suspended testing of its generic version of Rituxan (Rituximab), a $7-billion a year drug, at the third stage of clinical trials.
HAARETZ

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Pharma Blog Watch Clinic Becomes Pharma-Free Through Education, Staff Input GSK to Shut Down Tablet-Packaging Facility in Melbourne Global Recommendations on Child Medicine

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.